| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Hormel Institute, University of Minnesota, Austin, Minnesota 55912, USA
1Correspondence: The Hormel Institute, University of Minnesota, 801 16th Ave., N.E., Austin, MN 55912, USA. E-mail: eberdyshev{at}hotmail.com
The endocannabinoid signaling system is believed to play a down-regulatory role in the control of cell functions. However, little is known about the factors activating endocannabinoid synthesis and which of two known endocannabinoids, 2-arachidonoylglycerol (2-AG) or N-arachidonoylethanolamine (20:4n-6 NAE, anandamide), is of physiological importance. We approached these questions by studying a possible link between cell activation with 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor, PAF) and the generation of 2-AG and anandamide in human platelets and mouse P388D1 macrophages. Human platelets responded to stimulation with the production of various 1- and 2-monoacylglycerols, including 2-AG, whereas stimulation of P388D1 macrophages induced the rapid and selective generation of 2-AG, which was immediately released into the medium. The effect of PAF was receptor mediated, as PAF receptor antagonist BN52021 blocked the effect. The treatment did not change the content of anandamide in either macrophages or platelet-rich plasma. The inhibitors of PI- and PC-specific phospholipases C (U73122 and D609) as well as PI3-kinase inhibitor (wortmannin) attenuated PAF-induced 2-AG production in macrophages. These data suggest a direct role for the endocannabinoid system in controlling immune cell activation status and indicate that 2-AG rather than anandamide is the endocannabinoid rapidly produced in response to proinflammatory stimulation of immune cells.—Berdyshev, E. V., Schmid, P. C., Krebsbach, R. J., Schmid, H. H. O. Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells.
Key Words: anandamide • platelet-activating factor • macrophages • human platelets
This article has been cited by other articles:
|
|
 |
|
  S. Oka, J. Wakui, S. Ikeda, S. Yanagimoto, S. Kishimoto, M. Gokoh, M. Nasui, and T. Sugiura Involvement of the Cannabinoid CB2 Receptor and Its Endogenous Ligand 2-Arachidonoylglycerol in Oxazolone-Induced Contact Dermatitis in Mice J. Immunol., December 15, 2006; 177(12): 8796 - 8805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Rockwell, N. T. Snider, J. T. Thompson, J. P. Vanden Heuvel, and N. E. Kaminski Interleukin-2 Suppression by 2-Arachidonyl Glycerol Is Mediated through Peroxisome Proliferator-Activated Receptor {gamma} Independently of Cannabinoid Receptors 1 and 2 Mol. Pharmacol., July 1, 2006; 70(1): 101 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhao, Z. He, N. Chen, Y.-Y. Cho, F. Zhu, C. Lu, W.-y. Ma, A. M. Bode, and Z. Dong 2-Arachidonoylglycerol Stimulates Activator Protein-1-dependent Transcriptional Activity and Enhances Epidermal Growth Factor-induced Cell Transformation in JB6 P+ Cells J. Biol. Chem., July 22, 2005; 280(29): 26735 - 26742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Rademacher, S. Patel, W.-S. V. Ho, A. M. Savoie, N. J. Rusch, K. M. Gauthier, and C. J. Hillard U-46619 but not serotonin increases endocannabinoid content in middle cerebral artery: evidence for functional relevance Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2694 - H2701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oka, S. Yanagimoto, S. Ikeda, M. Gokoh, S. Kishimoto, K. Waku, Y. Ishima, and T. Sugiura Evidence for the Involvement of the Cannabinoid CB2 Receptor and Its Endogenous Ligand 2-Arachidonoylglycerol in 12-O-Tetradecanoylphorbol-13-acetate-induced Acute Inflammation in Mouse Ear J. Biol. Chem., May 6, 2005; 280(18): 18488 - 18497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kishimoto, M. Muramatsu, M. Gokoh, S. Oka, K. Waku, and T. Sugiura Endogenous Cannabinoid Receptor Ligand Induces the Migration of Human Natural Killer Cells J. Biochem., February 1, 2005; 137(2): 217 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oka, S. Ikeda, S. Kishimoto, M. Gokoh, S. Yanagimoto, K. Waku, and T. Sugiura 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils J. Leukoc. Biol., November 1, 2004; 76(5): 1002 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Walter, T. Dinh, and N. Stella ATP Induces a Rapid and Pronounced Increase in 2-Arachidonoylglycerol Production by Astrocytes, a Response Limited by Monoacylglycerol Lipase J. Neurosci., September 15, 2004; 24(37): 8068 - 8074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kishimoto, Y. Kobayashi, S. Oka, M. Gokoh, K. Waku, and T. Sugiura 2-Arachidonoylglycerol, an Endogenous Cannabinoid Receptor Ligand, Induces Accelerated Production of Chemokines in HL-60 Cells J. Biochem., April 1, 2004; 135(4): 517 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Witting, L. Walter, J. Wacker, T. Moller, and N. Stella P2X7 receptors control 2-arachidonoylglycerol production by microglial cells PNAS, March 2, 2004; 101(9): 3214 - 3219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, S. Batkai, P. Pacher, J. Harvey-White, J. A. Wagner, B. F. Cravatt, B. Gao, and G. Kunos Lipopolysaccharide Induces Anandamide Synthesis in Macrophages via CD14/MAPK/Phosphoinositide 3-Kinase/NF-{kappa}B Independently of Platelet-activating Factor J. Biol. Chem., November 7, 2003; 278(45): 45034 - 45039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kishimoto, M. Gokoh, S. Oka, M. Muramatsu, T. Kajiwara, K. Waku, and T. Sugiura 2-Arachidonoylglycerol Induces the Migration of HL-60 Cells Differentiated into Macrophage-like Cells and Human Peripheral Blood Monocytes through the Cannabinoid CB2 Receptor-dependent Mechanism J. Biol. Chem., June 27, 2003; 278(27): 24469 - 24475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sancho, M. A. Calzado, V. Di Marzo, G. Appendino, and E. Munoz Anandamide Inhibits Nuclear Factor-kappa B Activation through a Cannabinoid Receptor-Independent Pathway Mol. Pharmacol., February 1, 2003; 63(2): 429 - 438. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
